09/01/2009

CellaVision AB

CellaVision's new analyzer CellaVision® DM1200 presented

CellaVision AB (publ), which develops and sells digital morphology products for the routine analysis of blood and other body fluids, presents their new analyzer CellaVision® DM1200 at the international lab exposition AACC Annual Meeting & Clinical Lab Expo in Chicago, USA, on July 19-23. The product is commercially available in Europe and will be available in North America and Japan when CellaVision has received clearance from the respective countries' authorities.


"We see a substantial potential for this product on the European and North American markets as trends indicate that not only the large but also the medium-sized laboratories aim to streamline their analytical flow," says Yvonne Mårtensson, CEO of CellaVision. "This analyzer is powerful and flexible, and is intended to serve as a platform for future applications, giving CellaVision yet more of a competitive edge."

The CellaVision DM1200 replaces manual microscopy for analysis of blood samples and is aimed at clinical chemistry laboratories wishing to automate their manual differentials, making their analytical flow more efficient. The hardware is prepared for body fluid analysis.

The blood application is included in the CellaVision DM1200 and will be commercially available in Europe by the end of July. The application for body fluids is sold as a separate product and is intended to be released by the end of the year. The company is planning to apply for product registrations in Canada, the US and Japan.

CellaVision's current range of products includes the analyzers CellaVision® DM96 and CellaVision® DM8 as well as software for remote access, and proficiency testing and education - CellaVision® Remote Review Software and CellaVision® Competency Software. All of the products are compatible with each other and can be part of the same hospital network.

CellaVision DM1200 will be presented at the AACC in Chicago, USA, on the 19-23 of July 2009 in CellaVision's and Sysmex Amercia's show cases (238 and 2025 respectively). The convention is expected to draw 20,000 international visitors. For more details, please visit www.aacc.org.

For more product information and a product picture, please see below.


For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com


About CellaVision
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.

CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. CellaVision is traded under the ticker symbol CEVI and the ISIN code SE0000683484. The company's Certified Advisor is Remium AB.


Features and Benefits - CellaVision® DM1200
CellaVision DM1200 automates the work that is traditionally done by laboratory personnel using microscopes. The analyzer performs a preliminary WBC Differential and RBC Characterization, and provides functionality for platelet estimation. Using technology for digital image analysis, cells in blood can be classified automatically, which allows for both time reductions and more standardized analyses. The Medical Technologist performs the final verification on his or her computer screen. After signing off the result, it is automatically sent to the laboratory data system (LIS), where it is archived together with the patient record. The digital form of the analysis result provides other benefits, such as traceability and the ability to share results with colleagues within or outside the hospital, which increases sharing of expertise between units and makes them more productive and cost-effective.

CellaVision DM1200 is used after the cell counter has analyzed the sample and is compatible with all other CellaVision products. It can easily be a part of any hematology workflow.

Features
- Analysis of Peripheral Blood
- Prepared for Body Fluids
- Allows Digital Slides creation. Primarily for hematology smears, but also applicable to other types of specimens, such as Pathology, Cytology and Bone Marrow for research and educational purposes.
- Automated workflow - walk away
- Sample identification through barcode scanning and LIS query
- Automatic immersion oil dispensing
- Identification of the optimal analysis area
- WBC Differential
- RBC Characterization
- Pre-classification of blood cells into 18 classes (WBCs: 12, Non-WBCs: 6)
- Functionality for platelet estimation (PLT)
- Loading capacity: 12 slides
- Throughput: 20 slides/h (peripheral blood)
- Slide preparation methods (wedged): Automated slide maker and stainers or manual methods. Slides with clipped/round corners.
- Digital archiving of cell images and results together with the patient record.